-
-
-
-
-
-
-
CervoMed shows biomarker improvements in dementia trial
-
-
-
-
-
-
-
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
-
-
-
-
-
-
-
CervoMed reports positive 32-week trial data for dementia drug
-
-
-
-
-
-
-
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias
-
-
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

